Ryuvidine | B1808

Ryuvidine is a potent inhibitor of SET domain-containing protein 8 (SETD8) (IC₅₀ = 0.5 µM) that suppresses monomethylation of H4K20 in vitro. It displays weak inhibiton against cyclin-dependent kinase 4 (Cdk4; IC₅₀ = 6 µM for Cdk4/cyclin D1). Induces S phase accumulation in HEK293T cells. Cytotoxic against a range of human cancer cells.

Ryuvidine is a potent inhibitor of SET domain-containing protein 8 (SETD8) (IC₅₀ = 0.5 µM) that suppresses monomethylation of H4K20 in vitro. It displays weak inhibiton against cyclin-dependent kinase 4 (Cdk4; IC₅₀ = 6 µM for Cdk4/cyclin D1). Induces S phase accumulation in HEK293T cells. Cytotoxic against a range of human cancer cells.

B1808 | Ryuvidine DataSheet

Alternate Name/Synonyms: 2-Methyl-5-[(4-methylphenyl)amino]-4,7-benzothiazoledione

Appearance: Dark purple solid

Formulation: N/A

CAS Number: 265312-55-8

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₁₅H₁₂N₂O₂S

Molecular Weight: 284.33

Cell-Permeable?: Yes

Purity: ≥98%

Solubilities: DMSO (~5 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent inhibitor of SET domain-containing protein 8 (SETD8)

MDL Number: N/A

PubChem CID: 481747

SMILES: CC1=CC=C(C=C1)NC2=CC(=O)C3=C(C2=O)N=C(S3)C

InChi: InChI=1S/C15H12N2O2S/c1-8-3-5-10(6-4-8)17-11-7-12(18)15-13(14(11)19)16-9(2)20-15/h3-7,17H,1-2H3

InChi Key: HFPLHASLIOXVGS-UHFFFAOYSA-N